Compare AR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AR | ABVX |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | France |
| Employees | N/A | 69 |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.9B |
| IPO Year | 2013 | N/A |
| Metric | AR | ABVX |
|---|---|---|
| Price | $33.41 | $136.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 13 |
| Target Price | $47.13 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 4.8M | 2.2M |
| Earning Date | 04-29-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $5,275,823,000.00 | N/A |
| Revenue This Year | $29.74 | $52.14 |
| Revenue Next Year | $5.07 | $4,132.27 |
| P/E Ratio | $19.75 | ★ N/A |
| Revenue Growth | ★ 21.97 | N/A |
| 52 Week Low | $29.10 | $9.79 |
| 52 Week High | $45.75 | $148.83 |
| Indicator | AR | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 61.06 |
| Support Level | $32.85 | $106.03 |
| Resistance Level | $35.86 | $148.41 |
| Average True Range (ATR) | 1.02 | 5.48 |
| MACD | -0.04 | 1.74 |
| Stochastic Oscillator | 23.03 | 80.88 |
Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.